References |
1 |
Pharmacokinetic and pharmacologic variation between different estrogen products J Clin Pharmacol. 1995 Sep;35(9S):18S-24S. doi: 10.1002/j.1552-4604.1995.tb04143.x.
|
2 |
Simultaneous determination of estramustine phosphate and its four metabolites in human plasma by liquid chromatography-ionspray mass spectrometry Biomed Chromatogr. 2004 Jun;18(5):293-301. doi: 10.1002/bmc.319.
|
3 |
Differential uptake of estramustine phosphate metabolites and its correlation with the levels of estramustine binding protein in prostate tumor tissue Clin Cancer Res. 1998 Sep;4(9):2079-84.
|
4 |
Metabolism of estrone sulfate by normal breast tissue: influence of menopausal status and oral contraceptives
|
5 |
Resveratrol Inhibits Key Steps of Steroid Metabolism in a Human Estrogen-Receptor Positive Breast Cancer Model: Impact on Cellular Proliferation Front Pharmacol. 2018 Jul 10;9:742. doi: 10.3389/fphar.2018.00742.
|
6 |
The metabolism of estradiol; oral compared to intravenous administration J Steroid Biochem. 1985 Dec;23(6A):1065-70. doi: 10.1016/0022-4731(85)90068-8.
|
7 |
Profiling endogenous serum estrogen and estrogen-glucuronides by liquid chromatography-tandem mass spectrometry Anal Chem. 2009 Dec 15;81(24):10143-8. doi: 10.1021/ac9019126.
|
8 |
Cytochromes P450: a structure-based summary of biotransformations using representative substrates Drug Metab Rev. 2008;40(1):1-100. doi: 10.1080/03602530802309742.
|
9 |
FooDB:Estradiol acetate
|
10 |
Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 2005 Sep 28;227(2):115-24.
|
11 |
Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
|